本研究的目的是利用参加日本妇科肿瘤学组 (JGOG) 3017 研究的患者数据来确定卵巢透明细胞癌 (OCCC) 初始治疗后的最佳监测。 JGOG 研究评估了伊立替康和顺铂联合治疗方案与紫杉醇和卡铂治疗方案对接受初次手术的 OCCC 患者的疗效。本研究共纳入 619 名患者，以分析无进展生存期和总生存期，使用核平滑曲线来估计时间，以确定事件发生的峰值。按进展部位汇总进展事件的数量，并考虑竞争风险，估计主要进展部位的累积发生率。在治疗后 12 个月观察到进展或死亡的峰值风险，大多数事件是通过24 个月。死亡风险在治疗后 18 个月达到峰值，大多数事件在 48 个月时观察到。治疗后 18 个月内，肺、肝和脾转移的风险保持不变，此后呈下降趋势；大多数事件都是在 18 个月内观察到的。腹膜传播的危险在 12 个月内保持不变，此后呈下降趋势，大多数恶化情况是在 24 个月内观察到的。盆腔复发的风险在 6 个月时达到峰值，大多数恶化情况在 24 个月时观察到。OCCC 进展事件的发生率在 12 个月时达到峰值，大多数进展事件发生在 24 个月内。治疗后最初 24 个月内进行密切随访，此后减少就诊次数也是可以接受的。然而，密切监测症状并根据不同部位进展率的差异对患者进行检查可能很重要。版权所有 © 2024 Elsevier Inc. 保留所有权利。

This study was conducted to determine the optimal monitoring after initial treatment of ovarian clear cell carcinoma (OCCC) using data from patients enrolled in the Japanese Gynecologic Oncology Group (JGOG) 3017 study. The JGOG study evaluated the efficacy of an irinotecan and cisplatin combination regimen compared with that of a paclitaxel and carboplatin regimen for OCCC patients who underwent primary surgery.Yielding 619 total patients in this study, to analyze progression-free and overall survival, the hazards over time were estimated using kernel smoothing curves to identify the peak of event occurrence. The number of progression events was summed by progression site, and the cumulative incidence proportion was estimated for the major progression sites, considering competing risks.The peak hazard for progression or death was observed at 12 months post-treatment, and most events were observed by 24 months. The hazard for death peaked at 18 months post-treatment, with most events being observed by 48 months. The hazard for lung, liver, and spleen metastases remained constant for 18 months post-treatment, with a decreasing trend thereafter; most events were observed by 18 months. The hazard for peritoneal dissemination was constant for 12 months, with a decreasing trend thereafter, with most exacerbations observed by 24 months. The risk of pelvic recurrence peaked at 6 months, with most exacerbations observed by 24 months.The incidence of progression events for OCCC peaked at 12 months and most progression events occurred within 24 months. Close follow-up for the initial 24 months post-treatment and fewer visits thereafter may be acceptable. However, closely monitoring symptoms and examining patients based on differences in progression rates at different sites may be important.Copyright © 2024 Elsevier Inc. All rights reserved.